Here are five points:
1. Exalenz Bioscience and the Acute Liver Failure Study Group will study the ability of the BreathID Methacetin Breath Test to predict patient outcome in cases of acute liver failure.
2. The multicenter clinical study is expected to recruit up to 200 ALF patients over two years at 12 sites in the country.
3. The study is supported by the National Institute of Diabetes and Digestive and Kidney Diseases, an NIH Institute.
4. The study will be led by William M. Lee, MD, a liver disease expert from UT Southwestern Medical Center in Dallas and founder of the Acute Liver Failure Study Group.
5. Exalenz Bioscience develops diagnostic and monitoring systems that use the breath to diagnose and help manage GI and liver conditions.
More articles on GI/endoscopy:
3 points on the 2016 Gut Microbiota for Health World Summit
Central Illinois Endoscopy Center performs free colonoscopy for veterans
5 key thoughts from Dr. Brian Hudes on GI physician entrepreneurship
